EXAS Stock Recent News

EXAS LATEST HEADLINES

EXAS Stock News Image - investorplace.com

The ARK Innovation ETF (NYSEARCA: ARKK ) has come under the spotlight recently, and there are three Cathie Wood stocks to buy with strong buy ratings for investors to consider in May this year. One of the key characteristics of the ARK Innovation ETF is its concentrated portfolio, typically holding between 35 to 55 stocks.

investorplace.com 2024 May 17
EXAS Stock News Image - Zacks Investment Research

Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences' (EXAS) first-quarter top line.

Zacks Investment Research 2024 May 09
EXAS Stock News Image - Zacks Investment Research

Exact Sciences (EXAS) came out with a quarterly loss of $0.50 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.42 per share a year ago.

Zacks Investment Research 2024 May 08
EXAS Stock News Image - Zacks Investment Research

In the latest trading session, Exact Sciences (EXAS) closed at $63.24, marking a -0.46% move from the previous day.

Zacks Investment Research 2024 Apr 24
EXAS Stock News Image - Zacks Investment Research

Exact Sciences' (EXAS) first-quarter 2024 performance is expected to include gains from robust Cologuard uptake and continuing Oncotype DX growth, offset slightly by increasing operating costs.

Zacks Investment Research 2024 Apr 22
EXAS Stock News Image - Zacks Investment Research

Exact Sciences (EXAS) concluded the recent trading session at $63.22, signifying a -1% move from its prior day's close.

Zacks Investment Research 2024 Apr 17
EXAS Stock News Image - Zacks Investment Research

While the market has taken a small breather as of late, there have been many big-time winners throughout the last month, including these three. Analysts are bullish on their outlooks, with all three carrying a favorable Zacks Rank.

Zacks Investment Research 2024 Apr 10
EXAS Stock News Image - Business Wire

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present late-breaking data from the first analysis of the ASCEND-2 study demonstrating the compelling performance of its investigational multi-biomarker class, multi-cancer early detection (MCED) blood test. These results validate the sensitivity and specificity of the company's multi-biomarker class approach across a broad range of cancer types, including the m.

Business Wire 2024 Apr 08
EXAS Stock News Image - Business Wire

MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the company plans to release its first quarter 2024 financial results after the close of the U.S. financial markets on May 8, 2024. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress. First quarter 2024 webcast & conference call details Date:   Wedn.

Business Wire 2024 Apr 08
EXAS Stock News Image - InvestorPlace

Full disclosure, I'm not a tremendous fan of Cathie Wood. Generally, I think she makes some terrible picks.

InvestorPlace 2024 Apr 05
10 of 50